• Omnix Medical

  Participated · Series C · Oct 2025

  Founded in 2015, Omnix Medical is focused on discovering and developing novel antimicrobial peptide (AMP) therapies that address life-threatening, antibiotic-resistant infections. Its lead candidate, OMN6, rapidly destroys bacterial cell membranes and has received Fast-Track and Qualified Infectious Disease Product designations from the U.S. FDA. The company is currently running Phase II proof-of-concept trials targeting Gram-negative pathogens such as Acinetobacter baumannii, a major cause of hospital-acquired infections. Proceeds from recent funding will also support regulatory preparations, manufacturing scale-up, and advancement of additional AMP candidates in the pipeline. Unlike traditional antibiotics that target specific bacterial functions, OMN6’s pore-forming mechanism minimizes the chance of resistance development. Since inception, Omnix Medical has raised a total of $43 million to finance its R&D and clinical programs.

• Coologics

  Led · Seed · Apr 2025

  Coologics is developing Vlisse, a patented drug-free intravaginal cooling device intended to treat VVC, BV, and mixed vaginal infections by restoring the vaginal environment without antibiotics. The company positions Vlisse as a paradigm shift from traditional antifungal drugs and emphasizes reducing unnecessary antibiotic use. The recent oversubscribed seed financing will fund completion of an ongoing clinical trial, FDA submission, and initial market release. Coologics frames its technology as sustainable and focused on improving women’s health outcomes. The company’s leadership includes CEO/founder Dr. Kim Langdon and CMO Dr. Nicole Williams, who are alumni of Ohio State University and the University of Illinois, respectively. The announcement was issued from Cleveland on April 23, 2025.

• Triple Hair

  Participated · Equity · Jun 2024

  Triple Hair Group develops innovative treatments for men and women suffering from androgenic alopecia, including its flagship prescription product, Therapy-07. The company also markets drug-free patented OTC products for preventing hair loss and regaining hair density under the RIZN™ brand for men and Plenty Natural™ for women. Led by CEO and President Jean-Philippe Gravel, Triple Hair aims to provide clinically proven, accessible hair-regrowth solutions across early- and later-stage hair loss. It has Health Canada approval to begin Phase III clinical trials for Therapy-07 and is awaiting approvals in other jurisdictions, notably the US and Europe. The company intends to use recent funding to accelerate those Phase III trials and to prepare to begin trials in several countries. Triple Hair is based in Montréal, Canada.

No current team members are available.